Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2012-03-29

Clinical Trial Update: Amifostine to Protect the Rectum During External Beam Radiotherapy for Prostate Cancer [Phase 2]

View source ↗

Summary

This update reports the results of a Phase 2 trial evaluating amifostine to protect the rectum during external beam radiotherapy for prostate cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Amifostine (amifostine)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Prostatic Neoplasms | Phase 2 | Status: COMPLETED | Results posted: 2012-03-29